ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression.
Scott E, Archer Goode E, Garnham R, Hodgson K, Orozco-Moreno M, Turner H, Livermore K, Putri Nangkana K, Frame FM, Bermudez A, Jose Garcia Marques F, McClurg UL, Wilson L, Thomas H, Buskin A, Hepburn A, Duxfield A, Bastian K, Pye H, Arredondo HM, Hysenaj G, Heavey S, Stopka-Farooqui U, Haider A, Freeman A, Singh S, Johnston EW, Punwani S, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Heer R, Maitland NJ, Whitaker H, Pitteri S, Troyer DA, Wang N, Elliott DJ, Drake RR, Munkley J.
Scott E, et al.
J Pathol. 2023 Sep;261(1):71-84. doi: 10.1002/path.6152. Epub 2023 Aug 7.
J Pathol. 2023.
PMID: 37550801
Free article.
Our study identifies an important role for ST6GAL1 and alpha2,6 sialylated N-glycans in prostate cancer progression and highlights the opportunity to inhibit abnormal sialylation for the development of new prostate cancer therapeutics. 2023 The Authors. The Journal of Pathology p …
Our study identifies an important role for ST6GAL1 and alpha2,6 sialylated N-glycans in prostate cancer progression and highlights the oppor …